Since its start, Calibra has always been adhering to the strategy of combining translational multiomics research with development of clinical mass spectrometry products.  We are committed to conducting innovative research on finding novel clinical biomarkers using multiomics technologies. The discovery and validation of these novel biomarkers are conducted following basic life science research principles. We rely on the Danaher DBS lean management system to achieve quick registration/certification of novel biomarkers and related clinical diagnostic products, and provide our clients a one-stop solution from R&D to innovative clinical product development.